Stephen J. Schuster, M.D.

faculty photo
Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research
Attending Physician, Department of Medicine, Division of Hematology-Oncology, Hospital of the University of Pennsylvania
Director, Lymphoma Translational Research, Abramson Cancer Center of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-178
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 349-5330
Fax: 215-615-5888
B.S. (Psychology)
Saint Joseph's University, Philadelphia, PA, 1976.

Laboratory Research Technician, Division of Rheumatology, Hahnemann Medical College and Hospital, Philadelphia, PA, 1977.
Jefferson Medical College, Philadelphia, PA, 1981.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE.: Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 7: 4926-4935, Sep 2023.

Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, McGuirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO.: Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv 7: 4765-4772, Sep 2023.

Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG.: Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 402: 641-654, Aug 2023.

Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Alarcon Tomas A, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA.: Identifying an Optimal Fludarabine Exposure for Improved Outcomes after CD19 CAR T cell therapy for Aggressive B-NHL. Blood Adv Jul 2023.

Wudhikarn K, Tomas AA, Flynn JR, Devlin SM, Brower J, Bachanova V, Nastoupil LJ, McGuirk JP, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA.: Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv 7: 3192-3198, Jul 2023.

Tong Y, Udupa JK, Chong E, Winchell N, Sun C, Zou Y, Schuster SJ, Torigian DA.: Prediction of lymphoma response to CAR T cells by deep learning-based image analysis. PLoS One 18: e0282573, Jul 2023.

Shaw LC, Poussin M, Rodriguez-Garcia A, Eggold J, Minutolo NG, Wang J, Rook AH, Schuster SJ, Powell DJ.: TCRvBeta-CART therapy mediates high-precision targeting of malignant T-cell clones. Blood Adv 7: 1885-1898, May 2023.

Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, George SS, Pierini S, Krimitza E, Costabile F, Ghilardi G, Amelsberg KV, Lee YG, Pajarillo R, Markmann C, McGettigan-Croce B, Agarwal D, Frey N, Lacey SF, Scholler J, Gabunia K, Wu G, Chong E, Porter DL, June CH, Schuster SJ, Bhoj V, Facciabene A.: Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T-cell immunotherapy. Mol Ther 31: 686-700, Mar 2023.

Yegya-Raman N, Wright CM, LaRiviere MJ, Baron JA, Lee DY, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Maity A, Facciabene A, Paydar I, Plastaras JP.: Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clin Transl Radiat Oncol 39: 100587, Jan 2023.

Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells. Transplant Cell Ther 2023.

back to top
Last updated: 08/29/2023
The Trustees of the University of Pennsylvania